FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982163613> ?p ?o ?g. }

• W2982163613 endingPage "118771" @default.
• W2982163613 startingPage "118771" @default.
• W2982163613 abstract "Abstract The current study sought to formulate, optimize, and stabilize amphotericin B (AmB) loaded PEGylated nanostructured lipid carriers (NLC) and to study its ocular biodistribution following topical instillation. AmB loaded PEGylated NLC (AmB-PEG-NLC) were fabricated by hot-melt emulsification followed by high-pressure homogenization (HPH) technique. 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)] (mPEG-2K-DSPE) was used for surface PEGylation. mPEG-DSPE with different PEG molecular weight, 1 K, 2 K, 5 K, 10 K, and 20 K, were screened for formulation stability. Furthermore, the AmB loaded PEGylated (2K) NLC (AmB-PEG2K-NLC) was optimized using Box-Behnken design with respect to the amount of AmB, castor oil, mPEG-2K-DSPE, and number of high-pressure homogenization cycles as the factors; particle size, zeta potential, PDI, entrapment efficiency, and loading efficiency as responses. Stability of the optimized AmB-PEG2K-NLC was assessed over 4 weeks, at 4 °C as well as 25 °C and effect of autoclaving was also evaluated. AmB-PEG2K-NLC were tested for their in vitro antifungal activity against Candida albicans (ATCC 90028), AmB resistant Candida albicans (ATCC 200955) and Aspergillus fumigatus (ATCC 204305). Cytotoxicity of AmB-PEG2K-NLC was studied in human retinal pigmented epithelium cells. In vivo ocular biodistribution of AmB was evaluated in rabbits, following topical application of PEGylated NLCs or marketed AmB preparations. PEGylation with mPEG-2K-DSPE prevented leaching of AmB and increased the drug load significantly. The optimized formulation was prepared with a particle size of 218 ± 5 nm; 0.3 ± 0.02 PDI, 4.6 ± 0.1% w/w drug loading, and 92.7 ± 2.5% w/w entrapment efficiency. The optimized colloidal dispersions were stable for over a month, at both 4 °C and 25 °C. AmB-PEG2K-NLCs showed significantly (p   0.05) difference was not observed between the formulations tested. An optimized autoclavable and effective AmB-PEG2K-NLC ophthalmic formulation with at least one-month stability, in the reconstituted state, has been developed." @default.
• W2982163613 created "2019-11-01" @default.
• W2982163613 creator A5022102024 @default.
• W2982163613 creator A5022980710 @default.
• W2982163613 creator A5023933255 @default.
• W2982163613 creator A5025749067 @default.
• W2982163613 creator A5028081725 @default.
• W2982163613 creator A5039173092 @default.
• W2982163613 creator A5051632711 @default.
• W2982163613 creator A5051860282 @default.
• W2982163613 creator A5078051329 @default.
• W2982163613 date "2019-12-01" @default.
• W2982163613 modified "2023-09-29" @default.
• W2982163613 title "Optimization, stabilization, and characterization of amphotericin B loaded nanostructured lipid carriers for ocular drug delivery" @default.
• W2982163613 cites W1579046626 @default.
• W2982163613 cites W1888163363 @default.
• W2982163613 cites W1965258535 @default.
• W2982163613 cites W1974129624 @default.
• W2982163613 cites W1975717121 @default.
• W2982163613 cites W1980778944 @default.
• W2982163613 cites W1987908663 @default.
• W2982163613 cites W1998840608 @default.
• W2982163613 cites W1999642371 @default.
• W2982163613 cites W2006438089 @default.
• W2982163613 cites W2008370915 @default.
• W2982163613 cites W2010976109 @default.
• W2982163613 cites W2012409544 @default.
• W2982163613 cites W2018516156 @default.
• W2982163613 cites W2026935853 @default.
• W2982163613 cites W2028006420 @default.
• W2982163613 cites W2033390870 @default.
• W2982163613 cites W2047399850 @default.
• W2982163613 cites W2071631289 @default.
• W2982163613 cites W2081713406 @default.
• W2982163613 cites W2082660441 @default.
• W2982163613 cites W2082865634 @default.
• W2982163613 cites W2093032755 @default.
• W2982163613 cites W2094447110 @default.
• W2982163613 cites W2121842516 @default.
• W2982163613 cites W2137017984 @default.
• W2982163613 cites W2144149632 @default.
• W2982163613 cites W2156492800 @default.
• W2982163613 cites W2188985489 @default.
• W2982163613 cites W2190422594 @default.
• W2982163613 cites W2255754031 @default.
• W2982163613 cites W2318758594 @default.
• W2982163613 cites W2463532778 @default.
• W2982163613 cites W2468932732 @default.
• W2982163613 cites W2564470491 @default.
• W2982163613 cites W2591533405 @default.
• W2982163613 cites W2607384989 @default.
• W2982163613 cites W2653579398 @default.
• W2982163613 cites W2738403659 @default.
• W2982163613 cites W2739195081 @default.
• W2982163613 cites W2783778364 @default.
• W2982163613 cites W2802004570 @default.
• W2982163613 cites W2884562816 @default.
• W2982163613 cites W2973846764 @default.
• W2982163613 cites W4211161213 @default.
• W2982163613 cites W2125010860 @default.
• W2982163613 doi "https://doi.org/10.1016/j.ijpharm.2019.118771" @default.
• W2982163613 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7323935" @default.
• W2982163613 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31669555" @default.
• W2982163613 hasPublicationYear "2019" @default.
• W2982163613 type Work @default.
• W2982163613 sameAs 2982163613 @default.
• W2982163613 citedByCount "49" @default.
• W2982163613 countsByYear W29821636132020 @default.
• W2982163613 countsByYear W29821636132021 @default.
• W2982163613 countsByYear W29821636132022 @default.
• W2982163613 countsByYear W29821636132023 @default.
• W2982163613 crossrefType "journal-article" @default.
• W2982163613 hasAuthorship W2982163613A5022102024 @default.
• W2982163613 hasAuthorship W2982163613A5022980710 @default.
• W2982163613 hasAuthorship W2982163613A5023933255 @default.
• W2982163613 hasAuthorship W2982163613A5025749067 @default.
• W2982163613 hasAuthorship W2982163613A5028081725 @default.
• W2982163613 hasAuthorship W2982163613A5039173092 @default.
• W2982163613 hasAuthorship W2982163613A5051632711 @default.
• W2982163613 hasAuthorship W2982163613A5051860282 @default.
• W2982163613 hasAuthorship W2982163613A5078051329 @default.
• W2982163613 hasBestOaLocation W29821636132 @default.
• W2982163613 hasConcept C13245373 @default.
• W2982163613 hasConcept C16005928 @default.
• W2982163613 hasConcept C178790620 @default.
• W2982163613 hasConcept C185592680 @default.
• W2982163613 hasConcept C2779548794 @default.
• W2982163613 hasConcept C2779629538 @default.
• W2982163613 hasConcept C2779820397 @default.
• W2982163613 hasConcept C2780035454 @default.
• W2982163613 hasConcept C71924100 @default.
• W2982163613 hasConcept C98274493 @default.
• W2982163613 hasConceptScore W2982163613C13245373 @default.
• W2982163613 hasConceptScore W2982163613C16005928 @default.
• W2982163613 hasConceptScore W2982163613C178790620 @default.
• W2982163613 hasConceptScore W2982163613C185592680 @default.
• W2982163613 hasConceptScore W2982163613C2779548794 @default.
• W2982163613 hasConceptScore W2982163613C2779629538 @default.

• next